Loading stock data…
Summit Therapeutics Inc. (SMMT)
$17.28-0.32 (-1.85%)
Market ClosedLast close Sep 8
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Summit Therapeutics Inc. in the Healthcare sector is trading at $17.28 with a market capitalization of $10.5B. Wall Street consensus targets $28.44 (13 analysts), implying a +64.6% move over the next 12 months. The stock is currently 41% below its 52-week high of $29.23, remaining 5.3% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +64.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$220.50M↓ | -$195.21M↑ | -$224.88M↑ | -$234.21M↑ | -$568.44M |
| Net Income | -$215.70M↓ | -$189.42M↑ | -$219.17M↑ | -$231.79M↑ | -$565.71M |
Peer Comparison
JNJUNHPFE
Fundamentals
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-135.89%
Volume
Today's trading volume
7.34M
Recent News
Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab
Summit Therapeutics Inc. (NASDAQ:SMMT) said partner Akeso reported a statistically significant overall survival benefit for ivonescimab monotherapy over pembrolizumab in a prespecified interim analysis of Phase 3 HARMONi-2. The randomized, double-blind study enrolled 398 patients at 55 hospitals in China with previously untreated, PD-L1-positive advanced non-small cell lung cancer without sensitizing EGFR mutations or ALK […]
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
Summit Therapeutics (NASDAQ:SMMT) has seen its share price surge by 28.19 percent week-on-week, primarily driven by the positive results of an ongoing clinical trial for its bispecific antibody, ivonescimab. In an updated report during the week, the listed biopharmaceutical firm said that its China-based partner, Akeso Inc., saw positive overall survival results from the randomized […]
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.